A double-blind, stratified, randomised, parallel, placebo-controlled, multi-center study to assess the efficacy and safety of duloxetine (20mg bid for 2 weeks escalating to 40mg bid) for up to 12 weeks, compared to placebo, in community-dwelling elderly women greater than or equal to 65 years of age with symptoms of stress urinary incontinence or stress-predominant mixed urinary incontinence
Latest Information Update: 03 Sep 2021
Price :
$35 *
At a glance
- Drugs Duloxetine (Primary)
- Indications Mixed incontinence; Stress incontinence
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 26 Sep 2012 New source identified and integrated (German Clinical Trials Register: DRKS00004082).
- 24 Aug 2006 Status change
- 26 Nov 2005 New trial record.